Medicare will begin covering GLP-1 medications for obesity through the Medicare GLP-1 Bridge program starting July 1, 2026, offering eligible beneficiaries access for $50 per month
Storage and Shelf Life Unreconstituted (lyophilized) peptides are stable at room temperature for shipping but should be refrigerated (2-8 C / 36-46 F) upon arrival
Zepbound (tirzepatide) injection, for subcutaneous use
Weight loss, regardless of the method achieved, fundamentally alters how the body regulates temperature
Dose level, dose-escalation speed, baseline body weight, diabetes status, adherence, trial protocol, diet, activity, and side-effect tolerance all affect the observed timeline